GSK to Pay $950M for Pulmonary Hypertension Drug Aimed at Reducing Bleeding Risk

London, February 25, 2026 (Proactive) -- GSK has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, adding a clinical-stage pulmonary hypertension therapy to its pipeline. The company believes the drug could offer a safer alternative to existing treatments, which are often limited by bleeding complications. The global pulmonary hypertension market is projected to reach $18 billion by 2032.

The centerpiece of the deal is HS235, an activin signaling inhibitor that has completed Phase I trials in healthy volunteers. The program is preparing to enter further studies in two indications: pulmonary arterial hypertension and pulmonary hypertension associated with heart failure with preserved ejection fraction (HFpEF).

Read full article here.